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This study was aimed to investigate the eﬀect of NF-κB activity on the seizure susceptibility, brain damage, and P-gp expression
in kainic acid- (KA-) induced seizure rats. Male SD rats were divided into saline control group (NS group), KA induced epilepsy
group (EP group), and epilepsy group intervened with NF-κB inhibitor-pyrrolidine dithiocarbamate salt (PDTC group) or with
dexamethasone (DEX group). No seizures were observed in the rats of NS group. Compared with NS group, increased P-gp
expression and NF-κB activation in the rat brain of the EP group were observed after KA micro-injection. Both PDTC and
DEX pre-treatment signiﬁcantly increased the latency to grade III or V seizure onset compared to EP group but failed to show
neuron-protective eﬀect as the number of survival neurons didn’t signiﬁcantly diﬀer from that in EP group. Furthermore, PDTC
pre-treatment signiﬁcantly decreased P-gp expression along with NF-κB activation in the hippocampus CA3 area and amygdala
complex of rats compared with the EP group, implying that NF-κB activation involved in the seizure susceptibility and seizure
induced brain P-gp over-expression. Additionally, DEX pre-treatment only decreased P-gp expression level without inhibition of
NF-κBactivation,suggestingNF-κBindependentpathwaymayalsoparticipateinregulatingseizureinducedP-gpover-expression.
1.Introduction
Even though much progress has been made on the therapeu-
tic intervention for epilepsy, approximately 1/3 of epilepsy
patients who have been treated with 2 or more antiepileptic
drugs (AEDs) at the maximal tolerate dose are still suﬀering
from refractory epilepsy (RE) [1, 2]. Multidrug resistance
(MDR), which is one of the major causes of clinical drug-
therapy failure for epilepsy, was reported to be mediated
by P-glycoprotein (P-gp) overexpression, which has been
determined in human epileptogenic brain tissue resected
during epilepsy surgery and in brain of rats following the
prolonged status epileptic insults [3]. P-gp functions as
active pumps at the endothelial cell membrane of blood-
brain barrier (BBB) to prevent AEDs from reaching their
targets in the brain [4]. Therefore, inhibition of brain
P-gp overexpression under the epileptic conditions may
be a potential approach for RE treatments in the future.
However, the precise mechanisms underlining this brain P-
gp overexpression remain unclear.
P-gp is a protein encoded by the gene multidrug
resistance1 (MDR1) in human and mdr1a and mdr1b in
rodents, and it is expressed widely in epithelial cells of
many organs including the brain, liver, intestine, kidney,
adrenal gland, and testes [5]. It has been reported that
the expression level and the activity of P-gp on the BBB
was related to central nervous system (CNS) or peripheral
inﬂammation [6]. Since epilepsy is also considered as a
chronic inﬂammatory condition, one would expect there
might be a link between inﬂammation and brain P-gp
overexpression under epilepsy conditions. In support of this
hypothesis, Bauer et al. reported that P-gp expression level
was increased by extracellular glutamate at concentrations
similar to the epileptic brain, and this eﬀect was mediated2 Mediators of Inﬂammation
through the N-methyl-D-aspartic acid (NMDA) receptor
and cyclooxygenase-2 (COX-2) activation [7–9], as this
eﬀect was blocked either by the COX-2 inhibitors, such as
celecoxib,SC-58236, andNS-398orintheCOX-2 knock-out
mice.
N u c l e a rf a c t o r - k a p p aB( N F - κB), a key regulator of
immune and inﬂammatory response, has been implicated in
the neuropathological processes of seizure and epilepsy [10,
11]. The most widely characterized NF-κB subunits in CNS
are p50 and p65 [12]. Once activated, NF-κB translocates
to the nucleus and binds to the promoter region of target
genes by recognizing the DNA κB consensus elements. The
target gene products of NF-κB include many cytokines and
chemokines, cell adhesion molecules, and immunoreceptors
[13]. Previous studies have shown that inﬂammation can
regulate the expression of P-gp through NF-κB signaling
pathway at the BBB under several pathological conditions,
such as infection, tumor, and diabetes mellitus (DM) [14–
16]. Thus we hypothesized that the same signaling pathway
may also be responsible for the upregulation of P-gp
expression in the epileptic brain.
In the current paper, we investigated the expression
level of P-gp using a rat seizure model provoked by
intrahippocampal microinjection of kainic acid (KA). Two
distinct NF-κB inhibitors, pyrrolidine dithiocarbamate salt
(PDTC), and dexamethasone (DEX) were administrated to
the seizure rats to block NF-κB activation. Besides the P-
gp expression, the rat mortality, seizure susceptibility, and
brain damage were also analyzed. Our results demonstrated
that NF-κB inhibition attenuated the overexpression of P-
gp in the KA-induced seizure rats and decreased seizure
susceptibility without aﬀecting the rats’ mortality and brain
damage.
2.MaterialsandMethods
2.1. Animals. Adult male Sprague-Dawley rats weighing
140 ± 20g were purchased from Slack Shanghai Laboratory
Animal co., Ltd, (License No: (Shanghai) 2007-0005). Before
treatment in the experiments, all the rats were housed for 2
weeksatconstanttemperature22±1◦Candrelativehumidity
(60%)andhadfreeaccesstostandardfoodandwaterundera
ﬁxed 12h light/dark cycle. Procedures involving animals and
their care were conducted in conformity with the Guidance
Suggestions for the Care and Use of Laboratory Animal,
formulated by the Ministry of Science and Technology of
China [17].
2.2. Experimental Reagents and Instrument. Kainic acid
was purchased from Sigma (Louis, Mo, USA). Pyrroli-
dine dithiocarbamate (PDTC), a speciﬁc NF-κBa c t i v i t y
inhibitor, was purchased from International Laboratory
(USA). Dexamethasone Sodium Phosphate (DEX) was from
Jinyao (Tianjin, China). Monoclonal rabbit anti-Glucose
transporter 1 (GLUT-1) and antineuronal nuclear antigen
(NeuN, MAB377) antibody were from Chemicon (USA).
Monoclonal anti-P-glycoprotein (C219) antibody was pur-
chased from Abcam (England). Polyclonal anti-NF-κBp 6 5
(Catalog No.: 10745-1-AP) antibody was purchased from
ProteinTech Group, Inc (USA) and antiphospho-NF-κBp 6 5
antibody (Ser276, Cat No.: BS4135) was from Bioworld
Technology, Inc. (USA). TUNEL-based In Situ Apoptosis
Assay Kit (Cat: KGA7025) was from KeyGEN (Nanjing,
China). Lycra medical image acquisition and analysis system
waspurchasedfromLeica(Germany).Stereotacticapparatus
(H12070515) was from Huaibei Zhenghua (Anhui, China).
2.3. Seizure Induction with KA. F i f t yr a t sw e r er a n d o m l y
dividedintofourgroups,(1)salinecontrolgroup(NSgroup,
n = 8), (2) KA induced epilepsy group (EP group, n = 14),
(3) epilepsy intervened with PDTC pretreatment (PDTC
group, n = 14), and (4) epilepsy intervened with DEX
pretreatment (DEX group, n = 14). After being anesthetized
with 10% chloralhydrate (3.5mL/kg) by intraperitoneally
injection (i.p.), each rat was placed on the stereotaxic frame.
A hole was drilled in the skull with dental reamers. Using a
microinjector, seizure were induced by stereotactic-injection
of 3μL KA (0.5mg/mL) into the CA3 region of the left
hippocampus area (5.0mm posterior to the bregma, 5.0mm
left lateral from the midline, and 5.0mm deep from the
dura) according to the atlas of Paxions and Wastson [18].
Rats in the PDTC group and DEX group were pretreated
with PDTC (150mg/kg) or DEX (0.4mg/kg), respectively
by i.p injection for NF-κB inhibition 30min prior to KA
microinjection; while the NS group and EP group rats
received equivalent normal saline injection as a control [19].
After surgery, the scalps were sutured. Seizure activity was
assessed using behavioral observation and seizure scoring
according to Racine Scale [20]: 0, no reaction; I, stereotype
mounting, eye blinking, and/or mild facial clonus; II, head
nodding and/or several facial clonus; III, myoclonic jerks in
the forelimbs; IV, clonic convulsions in the forelimb with
rearing; and V, generalized, clonic convulsions associated
with loss of balance. Only rats that reached grade IV seizure
were selected for further analysis. Seizures were terminated
after 90min by administration of 10% chloralhydrate and
repeated as needed.
2.4. Observation of Seizures. Behavior study was performed
by 3 independent observers who were blinded to the sample
identity. According to the literature [21], the time ranged
from the initial injection of KA to grade III and V seizure
onset (the seizure onset time, denoted SOT3 and SOT5) was
recorded, respectively, as the latency index of the model rats
to evaluate seizure susceptibility.
2.5. Tissue Processing. Twenty-four hours after seizure,
models were established successfully, rats were perfused
transcardially with saline followed by 4% paraformaldehyde.
The brains were rapidly removed and ﬁxed in 10% formalin
phosphatebuﬀerfor24h.Thebraintissueswereﬁxedin10%
formalin neutral buﬀer for 24h, followed by dehydration
with alcohol, clearing inﬁltration, and paraﬃn embedding
within 4h
2.6. Immunohistochemistry. After being ﬁxed in acetone, two
or three sections of the following brain regions were chosen
for immunohistochemistry study: −2.3mm to −3.8mmMediators of Inﬂammation 3
relativetobregma,includingcerebralcortex,piriformcortex,
hippocampus CA3/CA4, dentate gyrus, amygdale complex,
and substantia nigra pars reticulata. CA3/CA4 was dened as
the CA area found in the hilus of the dentate gyrus. Brieﬂy,
slides were incubated with 0.03% H2O2 in PBS for 10min at
room temperature (RT), followed by 15min incubation with
5% normal goat serum in PBS. Sections were then incubated
with diﬀerent primary antibodies: anti-NF-κB p65 (1:40),
anti-p-NFκB-p65 (S276) (1:200), anti-P-gp (1:50), and
anti-NeuN (1:400) in 3% bovine albumin serum in PBS at
4◦C overnight. Immunoreactivity was tested with the avidin-
biotin-peroxidase technique, using 3,3
 -diaminobenzidine
(DAB) as the chromogen. Sections were dried, and then
dehydrated in graded alcohols, and mounted on the slides.
For the immunoﬂuorescence study, the transverse sec-
tions were blocked and then incubated in an antibody
mixture with antibodies against P-gp (C219, 1:100) and
GLUT-1 (1:1000). The slides were then washed for three
times followed by incubation with TRITC or FITC conju-
gatedsecondaryantibodies.Fluorescentsignalsfromdouble-
labeled sections were detected with a confocal microscope
(Leica TCS SP2; Leica, Benstein, Germany) and the images
were processed with Adobe Photoshop 6.0.
2.7. TUNEL Assay. TUNEL staning was performed as previ-
ously described with some modiﬁcations [22]. Brieﬂy, slides
were ﬁrstly incubated with 0.03% H2O2 in PBS for 10min
at room temperature, followed by proteinase K treatment
(7.5μLo f2 0μg/μL Proteinase K in 150mL 10mM Tris, pH
8.0). After rinsed twice with 1XPBS, the slides were then
incubatedwiththeTUNELreactionmixture(orcontrollabel
solution for negative control) to label the DNA fragments
in the cell with the digoxigenin-nuclotide. FITC-conjugated
antidigoxigenim antibody was then applied to detect the
TUNEL-positive cells with ﬂuorescence microscopy.
2.8. Cell Counting. Cell counting was performed by 3 inde-
pendent observers who were blinded to the sample identity.
For each rat, the positive cells were counted in 5 ﬁelds
of each slide with a 40x objective lens. The representative
high-power nonoverlapping ﬁelds of the interesting areas
were captured using an Olympus Fluor view laser scanning
confocal microscope. The areas examined included the
hippocampus CA3 area, dentate gyrus, and amygdaloid
nuclear complex. Data obtained in each ﬁeld per slice were
added together to make a single ﬁnal data for each slice.
Values of two slices per rat were averaged and this value was
used to calculate the percentage of NeuN, NF-κB, or P-gp
positive cells. A frequency score was assigned for each cell-
type using 4 distinct grades: I, ≤25% (rare); II, 26%–50%
(sparse); III, 51%–75% (high); IV, >75% (all). Although this
cell counting method has some limitations as compared to
design-based stereological analysis [23], the occurrence of
any bias in counting neurons or other cells should similarly
aﬀect control and experimental samples since these samples
underwent the same methodological procedures in parallel.
2.9. Data Analysis. Where applicable, data were presented
as means ± standard deviation, and the expression levels of
NF-κB and P-gp were described as ranked data. Statistical
analysis was carried out using the SPSS software (13.0).
Statistical diﬀerences were evaluated by ANOVA followed by
theLSDposttestformultiplecomparisons.Rankeddatawere
evaluatedbyKruskal-WallistestandWilcoxonranksumtest.
A P value below .05 was considered statistically signicant.
3. Results
3.1. The Seizure Susceptibility of kainate-Treated Rats after
NF-κB Inhibition. No seizures were observed in the rats of
NS group. About 86% of KA micro-injected rats (36 out of
42) developed status epilepticus (SE), which matched to the
study criterion. Each of EP, PDTC, and DEX group has 2
rats died of severe seizures after KA injection. Finally there
were 12 rats in the EP group, PDTC group, and DEX group
respectively,and8ratsintheNSgroup.AsshowninFigure 1,
the seizure latencies of rats pretreated with PDTC or DEX
w e r ep r o l o n g e di nc o n t r a s tw i t hE Pg r o u p .T h em e a nv a l u e
for the seizure onset time to grade III (SOT3) was 89.58 ±
39.28min and 87.92 ± 45.80min for the PDTC and DEX
groups, respectively, compared to 67.50 ± 22.91min for the
EP group. Similarly, SOT5 in the PDTC and DEX pretreated
groups was 104.17 ± 39.07min and 103.33 ± 51.27min,
respectively, signiﬁcantly longer than 74.58 ± 22.10min for
the EP group.
3.2. Cell Lose in kainate-Treated Rats after NF-κB Inhibition.
In the control NS group, the pyramidal cells of hippocampus
CA3arearevealedatypical4to5layersstructurewithclosely
aligned cells and clear nuclei. However, in the EP group,
24h after KA injection, the brain structures were markedly
damaged, evident by tissue edema as well as neuronal
degeneration and loss in the CA3 area of hippocampus
and amygdaloid nuclear complex. The number of surviving
neuronswas64.75±16.89/HF,114.00±26.87/HF,and65.75±
16.34/HF in the CA3 area, dentate gyrus and amygdaloid
nuclear complex in NS group rats, respectively. Compared
to the NS group, the numbers of survival neurons in the
hippocampus CA3 area (19.00 ± 10.18/HF, P = .000) and
amygdaloid nuclear complex (49.42 ± 11.20/HF, P = .017)
signiﬁcantly declined in the EP group (P<. 05), except for
thedentategyrusarea(104.50±17.38/HF,P>. 05).Although
PDTC (21.25±6.98/HF, 104.42±17.46/HF, 52.83±9.77/HF)
and DEX (18.50 ± 8.65/HF, 114.67 ± 12.63/HF, 55.26 ±
9.41/HF) pretreatment shows a slightly neuron-protective
eﬀect compared to the EP group, it did not reach statistical
signiﬁcance (P>. 05). Furthermore, no signiﬁcant structure
changes could be observed in the dentate gyrus among the
three KA induced groups (Figure 2(a)).
In order to detect cells undergoing apoptosis in the
brain tissue, TUNEL assay was performed. As shown in the
Figure 2(b), a few TUNEL-positive cells were scattered in the
brains of NS group rats. 24h after KA micro-injection, the
TUNEL-positive cell numbers did not increase signiﬁcantly
compared to the NS group (P>. 05). In addition, no
signiﬁcant diﬀerence in TUNEL staining was observed
b e t w e e nD E Xg r o u pa n dK Ag r o u p ,o rb e t w e e nP D T Cg r o u p
and KA group (P>. 05). These results indicate that the4 Mediators of Inﬂammation
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Figure 1: PDTC and DEX pretreatment prolonged the seizure onset time in KA induced rats. Mean values for the seizure onset time to
grade III (SOT3, A) and grade V (SOT5, B) as the latencies to seizure of each group. SOT3 in the PDTC and DEX pretreated groups was
89.58 ±39.28min and 87.92 ±45.80min, respectively, compared to 67.50 ±22.91min in EP group. SOT5 in the PDTC and DEX pretreated
groups was 104.17 ± 39.07min and 103.33 ± 51.27min, respectively, compared to 74.58 ± 22.10min in EP group. (∗P<. 05, versus EP
group).
Table 1: NF-κB p65 expression in each group (the number of
cases).
groups CA3 area DG AMYG
I II III IV I II III IV I II III IV
N S g r o u p 7 1008 0005 300
E P g r o u p 1 4252 4421 326
P D T C g r o u p 8 4007 5003 630
D E X g r o u p 63 0 348 0 023 6 1
P∗ P = .001 P = .000 P = .002
EP versus NS P = .001 P = .003 P = .001
PDTC versus EP P = .001 P = .006 P = .015
DEX versus EP P = .057 P = .025 P = .141
Note: Values are presented as 4 distinct grades: I: ≤25% (rare); II: 26%–50%
(sparse); III: 51%–75% (high); IV: >75% (all), according to the proportions
of NF-κBp o s i t i v ec e l l s .∗The overall diﬀerence among 4 groups using the
Kruskal-Wallis test. DG: dentate gyrus; AMYG: amygdaloid nuclear.
KA induced brain cell loss is primarily through a necrotic
mechanism instead of apoptosis mechanism (Figure 2(b)).
3.3. The Brain Expression of NF-κBp 6 5a n dP - g p .In NS
group rats, only several NF-κB p65 and P-gp immunopos-
itive cells in the brain were detected. Compared to the NS
group, the numbers of the NF-κBp 6 5a n dP - g pp o s i t i v e
cells signiﬁcantly increased in the EP group. As shown in
Figure 3(a),N F - κB p65 was widely expressed in neurons,
glial cells, and vascular endothelial cells in the EP group 24h
after KA micro-injection. In addition, the p65 signal was also
frequently detected in the cell nuclei and more prominently
in hippocampus CA3 area, suggesting the activation of NF-
κB in the epileptic brain. Meanwhile, the expression level of
Table 2:P-gpexpressionintheratbrainofeachgroup(thenumber
of cases).
groups CA3 area DG AMYG
I II III IV I II III IV I II III IV
N S g r o u p 710080008 000
E P g r o u p 029124602 361
P D T C g r o u p 75 0 01 02 0 075 0 0
D E X g r o u p 0 1 02056012 361
P∗ P = .000 P = .000 P = .001
EP versus NS P = .000 P = .001 P = .001
PDTC versus EP P = .000 P = .001 P = .004
DEX versus EP P = .001 P = .058 P = .029
Note: Values are presented as 4 distinct grades: I: ≤25% (rare); II: 26%–50%
(sparse); III: 51%–75% (high); IV: >75% (all), according to the proportions
of P-gp positive cells. ∗The overall diﬀerence among 4 groups using the
Kruskal-Wallis test. DG: dentate gyrus; AMYG: amygdaloid nuclear.
P-gp was also signiﬁcantly increased in the EP group and
the major positive cells were vascular endothelial cells in the
brain. Compared to the EP group, the expression of NF-κB
p65 and P-gp was decreased in the PDTC group, and the
location of NF-κB p65 was changed to the cytoplasm instead
of nuclei with shallow staining, suggesting a decreased NF-
κB activation by the PDTC pretreatment.Interestingly, in the
DEX group, even P-gp expression was declined compared to
the EP group; the expression level and distribution of NF-κB
p65 was not signiﬁcantly diﬀerent from the EP group as that
happened in the PDTC pretreated epileptic rats. (Tables 1
and 2 and Figures 3(a) and 4). Collectively, the above data
shows the level of NF-κB activation is closely related with the
expression level of P-gp in the KA induced epileptic brain.Mediators of Inﬂammation 5
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Figure 2: PDTC and DEX pretreatment failed to prevent KA induced brain cell loss. (a) Representative photos of immunohistochemistry
staining with anti-NeuN antibody (×100). Immunohistochemistry staining was performed to check the surviving neurons in the brain. The
shape and number of neurons is normal in NS group (NS),while signiﬁcant neuronal loss in the CA3 area was observed 24h after KA micro-
injection in the EP group (EP). In the KA induced rat pre-treated with PDTC (PDTC) or DEX (DEX), the survival neuron numbers did not
signiﬁcantly increase compared to the EP group. Additionally, the neuron number in dentate gyrus was not signiﬁcantly changed among
the four groups. Histogram showed the number of surviving neurons in the indicated brain area of each group (/HF). ∗P<. 05 versus NS
group; ∗∗P<. 01 versus NS group; #P>. 05 versus EP group, CA3, hippocampus CA3 area; DG: dentate gyrus; AMYG: amygdaloid nuclear.
(b) Representative photos of TUNEL staining (times 200). Cells undergoing apoptosis were detected (labeled by FITC and shown in green)
in each group 24h after KA or vehicle injection. KA injection did not increase TUNEL positive cells signiﬁcantly; there was no diﬀerence in
TUNEL positive cell numbers between PDTC/DEX and EP groups. CA3, P = .052; DG, P = .65; AMYG, P = .061, by ONEWAY-ANOVA
test; CA3, hippocampus CA3 area; DG: dentate gyrus; AMYG: amygdaloid nuclear.
To conﬁrm these ﬁndings, another antibody against
activated NF-κB, antiphospho- NF-κB p65 (S276) was used
in the immunohistochemistry. As shown in Figure 3(b),o n l y
a few phospho-p65 positive cells could be detected in the
normal brain tissue; while the phospho-p65 positive cell
number signiﬁcantly increased in the EP group, conﬁrming
the activation of NF-κB after KA micro-injection in brain.
Similar to the above NF-κB p65 staining result, phospho-
p65 positive cell numbers also signiﬁcantly decreased in the
P D T Cg r o u pc o m p a r e dt ot h eE Pg r o u p( C A 3a n dA M Y G ,
allP = .000),andDEXpretreatmentdecreasedphospho-p65
positive cell numbers compared to the EP group as well but
did not reach statistic signiﬁcance (P = .09, Figure 3(b)).
ToexcludethepossibilitythatthedecreasedP-gpstaining
in the PDTC and DEX group compared with EP group
was due to cell loss, an immuno-ﬂuorescence staining
experiment was performed with an anti-GLUT1 antibody
paired with FITC conjugated secondary antibody, which will
speciﬁcally label endothelial cells in the tissue. As shown in
Figure 5,endothelialcellnumberdidnotchangesigniﬁcantly
betweenPDTCandEPgrouporbetweenDEXandEPgroup.
As the previous NeuN staining also showed similar neuron
numbers in these three groups, we think the decreased
staining of P-gp in the rat brain of PDTC and DEX group
was most likely due to the decreased expression level rather
than the decreased cell numbers.
4. Discussion
The multidrug resistance (MDR) gene encodes a family of
proteins including P-gp that belong to the ATP-binding
cassette (ABC) transporter family [24]. P-gp, which has
been studied extensively, plays a critical role in the etiology
of RE by limiting AEDs into their targets in the brain.
Several traditional AEDs such as carbamazepine, Phenobar-
bital, and phenytoin are the transport substrates of P-gp6 Mediators of Inﬂammation
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Figure 3:PretreatmentofPDTC,butnotDEX,decreasesKAinducedNF-κBactivation.(a)Representativephotosofimmunohistochemistry
staining with anti- NF-κB p65 antibody (×400). NF-κB expression and distribution pattern was detected in the rat brains of each group
24h after KA or vehicle micro-injection. The NF-κB p65 immunoreactive cell number increased as well as more nuclear staining was
observed in the EP group (EP) compared to the control rat (NS). By contrast with EP group, the number of NF-κBp 6 5p o s i t i v ec e l l s
were decreased in the group pre-treated with PDTC (PDTC), but not in the group with DEX pretreatment (DEX). (b) Representative photos
of immunohistochemistry staining with antiphospho-NF-κB p65 antibody (×400). Activated NF-κB in the rat brains of each group was
detected 24h after KA or vehicle micro-injection. The number of Phospho-p65 positive cells signiﬁcantly increased 24h after KA injection
(EP) compared with that in NS group. Compared to the EP group, activated NF-κB signal was signiﬁcantly decreased in hippocampus CA3
areaandamygdaloidnuclearcomplexoftheratspre-treatedwithPDTC(PDTC),butnotintheratswithDEXpretreatment(DEX). #P<. 05
versus NS group; ##P>. 05 versus NS group; ∗P<. 05 versus EP group; ∗#P>. 05 versus EP group CA3, hippocampus CA3 area; DG: dentate
gyrus; AMYG: amygdaloid nuclear.
[25]. P-gp brain expression is increased under prolonged
seizure conditions such as status epilepticus or frequent
spontaneous seizures [26], and selective inhibition of P-
gp could enhance the brain uptake of AEDs and therefore
improve their anticonvulsant eﬀects [4, 5]. For example,
P-gp speciﬁc inhibitors, such as tarquidar (TQD, XR9576)
and PS833, were reported to improve the anticonvulsive
eﬀects of AEDs by competitively inhibiting P-gp transport
activity [27]. However, these competitive inhibitors reverse
MDR at concentrations that usually result in unacceptable
toxicity in the clinical trials [28]. Recently, novel tech-
nologies, such as antisense oligonucleotides, ribozymes, and
the RNA interference, have also been applied to block the
upregulation of brain P-gp after epileptic assaults, but the
clinical application of these techniques are still not practical
[29]. Therefore, searching for other approaches to inhibit the
seizure upregulated P-gp expression and functions are still
necessary for the eﬃcient RE patients’ treatment.
Inﬂammation is an important biological process that
is activated after SE or prolonged seizure [30]. Mounting
evidence supports that inﬂammation not only contributes to
epileptogenesis but also is involved in RE induced neuronal
injury [31]. NF-κB, a major regulator of inﬂammation, has
been linked with epilepsy in many reports. Overexpression
of NF-κB in the brain hippocampus has been observed
both in the experimental models of epilepsy [32] and inMediators of Inﬂammation 7
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Figure 4: Pretreatment of PDTC and DEX both decreases KA induced P-gp overexpression. P-gp expression was detected by
immunohistochemistry staining (×400) with an anti-P-gp antibody. A few P-gp positive cells were observed in the control NS group (NS).
The number of the P-gp immunoreactive cells signiﬁcantly increased in the KA micro-injected brain of EP group (EP), and it was mainly
in vascular endothelial cells. By contrast with EP group, P-pg immunoreactive cells were decreased similarly in KA micro-injected brains
pre-treated with PDTC (PDTC) or DEX (DEX). ↓: Neurons; ←:glial cells; →: vascular endothelial cells.
hippocampus tissues surgically removed from patients with
temporal lobe epilepsy [33]. Yu et al. reported that NF-
κB mediated TNF-induced upregulation of mdr1 promoter
activity by selectively binding p65 to mdr1, suggesting
inﬂammation enhances BBB eﬄux transport through NF-
κBa c t i v a t i o n[ 34]. However, whether P-gp overexpression
in the epileptic brain is mediated through NF-κBa c t i v a t i o n
remains unclear. Therefore,the present study mainly focused
on the relationship between NF-κB activation and P-gp
expression in the brain of KA induced seizure rats. To
avoid the toxicity of systemic administration, we established
a seizure rat model by using KA microinjection into the
hippocampus area. Here we reported that, 24h after the
onset of KA induced seizures, the brain expression of P-
gp was signiﬁcantly increased in the hippocampus CA3
area and amygdala complex, which are important brain
regions for epileptogenesis [35], and this eﬀectwasabolished
in the rats pretreated with PDTC, a selective inhibitor of
NF-κB by blocking IκB-ubiquitin ligase activity [36]. This
data suggests that NF-κB activation plays an important
role in the upregulation of P-gp expression in the seizure
brain. Our data is consistent with Bauer’s research which
showed that inhibition of NF-κB by the SN50 peptide could
block the inductive eﬀect of the proinﬂammatory cytokines
on P-gp upregulation in the isolated rat brain capillaries
[37].
Furthermore, our data with DEX treatment suggested
some other NF-κB independent pathway may also be
involved in the upregulation of P-gp in the KA induced
seizure rat brain, as DEX pretreatment decreased the
P-gp expression without signiﬁcantly inhibiting NF-κBP 6 5
expression in hippocampus CA3 and amygdala complex
area. For example, some other transcription factors such
as activator protein-1 (AP-1) [38] and pregnane xenobiotic
receptor (PXR) have been reported to be also involved in
the regulation of P-gp expression under many pathological
conditions and their activation can be regulated by DEX
[39]. Therefore, DEX may decrease the KA induced brain
P-gp expression through regulation of these transcription
factors instead of NF-κB activation. Further experiments
are needed to explore the precise mechanisms regarding
the inhibition eﬀect of DEX on the P-gp overexpression in
the epileptic brain. On the other hand, it is noteworthy
that the two NF-κB inhibitors used in the current report,
PDTC and DEX, also have many other pharmacology eﬀects
besides inhibition of NF-κB signal pathway. For example,
PDTC also has eﬀect on nitric oxide synthetase and interfere
with nitric oxide production. Therefore, further experiments8 Mediators of Inﬂammation
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Figure 5: Pretreatment of PDTC and DEX did not change endothelial cell numbers compared with EP group. Representative photos of
immuno-staining with anti-GLUT1 antibody (×200). Endothelial cells in the rat brains of each group were labeled with an anti-GLUT1
antibody paired with a FITC conjugated secondary antibody (shown in green). No signiﬁcant diﬀerence in endothelial cell numbers could
be detected between PDTC/DEX and EP group.
with SiRNA technique to speciﬁcally block down NF-κB
p65 or p50 will be helpful to provide more direct and
speciﬁc evidence about the role of NF-κBa c t i v a t i o ni nP - g p
overexpression in the epileptic brain.
NF-κB is a pluripotent nuclear transcripton factor
implicated in the regulation of multiple cellular processes,
including the inﬂammatory response, cell apoptosis and
survival [40, 41]. However, the role of NF-κB inhibition on
seizureactivityaswellasseizureinducedbraindamageisstill
unclearandcontroversial.Shinetal.hadreportedthatPDTC
prevented hippocampal neuronal loss in the KA induced
seizure model [42]; whereas Mattson’s work showed that
intrahippocampal injection of IκB decoy DNA to block NF-
κB activation prior to KA administration enhanced neuronal
cell death [43]. Recently, Lubin et al. [44] has reported that
the seizure susceptibility of KA induced-seizure rats was
increasedafterNF-κBactivityinhibition.Thereasonsforthis
discrepancy might be (1) diﬀerent approaches were applied
for the NF-κB inhibition: recent study found that diﬀerent
regulator of NF-κB could interfere with a speciﬁc subset
of target genes’ expression and then shows diﬀerent eﬀects
on cell death or survival [43]; (2) distinct observation time
points were chosen. In the present study, we found that the
inhibition of NF-κB by PDTC and DEX pretreatment failed
to show neuron-protective eﬀect in the KA induced epileptic
brain as the number of survival neurons did not signiﬁcantly
diﬀerfromthatinEPgroup.Thepossiblereasonsforthelack
of neuron-protective eﬀect of NF-κB inhibition in our study
might include (1) some NF-κB independent mechanisms
might mediate the KA induced neuron loss in our epilepsy
model;(2)bothPDTCandDEXalsocouldaﬀectothersignal
pathways besides the NF-κB inhibition; (3) NF-κBa c t i v a t i o n
inthisepilepsymodelmightevenhavesomeprotectioneﬀect
on the cell death. Further studies with NF-κBS i R N Ao rI κB
overexpressionwouldbemoreusefultochecktheroleofNF-
κB activation in the epileptic brain’s neuron loss.
In the current study, even both PDTC and DEX pre-
treatment inhibit the brain overexpression of P-pg and
decrease seizure susceptibility in our KA micro-injection
induced seizure model, no signiﬁcant changes regarding the
seizure rats’ mortality and brain damage were observed.
This result suggests that the overexpression of P-gp in the
seizure brain alone is not neuron-toxic; its deleterious eﬀect
in the developing of RE is mediated through the enhanced
AED drug eﬄux. Further experiments to observe the index
of seizure susceptibility, severity, and brain damage in KA
induced seizure rats with a combined treatment of AED and
PDTC or DEX would be of more clinical importance.
5. Conclusions
Taken together, the present study reports that inhibition of
NF-κB activation by PDTC could block the seizure induced
brain P-gp overexpression and extend the seizure onset
time, implying NF-κB activation involved in the seizure
susceptibilityandseizureinducedbrainP-gpoverexpression.
However, this inhibition did not change the seizure rats’
brain damage and mortality. In addition, DEX reduced P-
gp overexpression without signiﬁcantly changing NF-κBp 6 5
expression, suggesting NF-κB independent pathway may be
also involved in the seizure induced P-gp overexpression.
Further studies are needed to address whether inhibiting
NF-κB activation could enhance the eﬃcacy of AEDs to
overcome pharmacoresistance in a chronic drug-resistant rat
model.
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